Drugs / Dental pulp mesenchymal stem cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04302519 | Mar 2020 → Jun 2021 | COVID-19 | CAR-T (Shanghai) Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT04130100 | Apr 2019 → Sep 2021 | osteoarthritis, knee | CAR-T (Shanghai) Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dental pulp mesenchymal stem cells | “To evaluate the clinical efficacy and safety of dental pulp mesenchymal stem cells in the treatment of primary mild to moderate knee osteoarthritis through a comparative study...” NCT04130100 ↗ |
| Modality | Cell therapy | “20 participants will receive low dose of dental pulp mesenchymal stem cells, 20 participants will receive high dose” NCT04130100 ↗ |
| Route | Other | “Patients receiving intraarticular injection of low dose of mesenchymal stem cells.” NCT04130100 ↗ |